Trial Profile
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- 08 Oct 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2021.
- 04 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 16 Sep 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.